NCT06576635View on ClinicalTrials.gov

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
NSCLC
Interventions
DRUG

Docetaxel

75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle

DRUG

Paclitaxel

135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle

DRUG

Gemcitabine

"1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)"

DRUG

Pemetrexed

500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle

DRUG

Vinorelbine

30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER

NCT06576635 - LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients | Biotech Hunter | Biotech Hunter